Minerva Neurosciences is a biotechnology business based in the US. Minerva Neurosciences shares (NERV) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $1.70 – a decrease of 5.03% over the previous week. Minerva Neurosciences employs 8 staff and has a market cap (total outstanding shares value) of 0.00.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $1.70 |
|---|---|
| 52-week range | $1.15 - $3.69 |
| 50-day moving average | $1.67 |
| 200-day moving average | $2.32 |
| Wall St. target price | $5.00 |
| PE ratio | 9.2632 |
| Dividend yield | N/A |
| Earnings per share (TTM) | $0.19 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.7 from 2025-05-02
| 1 week (2025-04-25) | -3.41% |
|---|---|
| 1 month (2025-04-04) | 24.09% |
| 3 months (2025-02-05) | -28.57% |
| 6 months (2024-11-05) | -27.97% |
| 1 year (2024-05-03) | -28.27% |
|---|---|
| 2 years (2023-05-04) | -63.12% |
| 3 years (2022-05-04) | 4 |
| 5 years (2020-05-04) | 78 |
Valuing Minerva Neurosciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Minerva Neurosciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Minerva Neurosciences's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 9x. In other words, Minerva Neurosciences shares trade at around 9x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
| Gross profit TTM | $-11,898,595 |
|---|---|
| Return on assets TTM | -29.04% |
| Return on equity TTM | -675.09% |
| Profit margin | 0% |
| Book value | $-3.67 |
| Market Capitalization | $12.3 million |
TTM: trailing 12 months
We're not expecting Minerva Neurosciences to pay a dividend over the next 12 months.
Minerva Neurosciences's shares were split on a 1:8 basis on 20 June 2022 . So if you had owned 8 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Minerva Neurosciences shares – just the quantity. However, indirectly, the new 700% higher share price could have impacted the market appetite for Minerva Neurosciences shares which in turn could have impacted Minerva Neurosciences's share price.
Over the last 12 months, Minerva Neurosciences's shares have ranged in value from as little as $1.15 up to $3.69. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Minerva Neurosciences's is -0.098. This would suggest that Minerva Neurosciences's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Minerva Neurosciences has bucked the trend.
Minerva Neurosciences, Inc. , a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of negative symptoms in patients with schizophrenia. The company also has exclusive rights to develop and commercialize MIN-301, a soluble recombinant form of the Neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts. .
Track the progress of the S&P 500 stocks to make more informed investment decisions.
See our picks for the best brokers for trading S&P 500 stocks, ETFs, options and futures.
These are the stocks to buy when you don’t have much to spend.
Explore the best bonuses for opening a new brokerage account.
Stock lending allows investors to loan out their existing stocks, although it has both advantages and disadvantages.
Compare pros, cons, research tools and reviews for these two trading platforms.
Some of the best trading apps like Robinhood are SoFi, Tastytrade, Public, eToro, Acorns, Interactive Brokers, E*TRADE and more.
Compare pros, cons, research tools and reviews for these two trading platforms.
SoFi Invest is a no-fee commissions platform with both active and automated investment accounts.
Webull is a broker with zero-commission trading and a suite of tools to help you invest.